Our Clinical Trials
The Sean N. Parker Center for Allergy & Asthma Research at Stanford University conducts many clinical trials with the goal of developing therapies for allergic disorders and asthma.
Currently Recruiting Clinical Trials & Studies
The purpose of this study is to evaluate the safety and efficacy of a novel desensitization method, called EPicutaneous ImmunoTherapy (EPIT) with the Viaskin® Peanut patch in young children between the ages of 1 and 3 years with peanut allergy. The Viaskin® Peanut is an investigational medication using a specially designed patch applied on the skin that contains a dry extract of peanut proteins. The Viaskin® Peanut patch is designed to desensitize a peanut-allergic person. If your child has a diagnosed peanut allergy, but is otherwise healthy and in between the ages of 1 and 3 years, he/she may be eligible to participate. Additional eligibility criteria require that the child is currently following a strict peanut-free diet and that the child has no prior history of any immunotherapy to any food. If your child qualifies for the study, he/she will receive the treatment, study-related procedures and exams at no cost.
The purpose of this study is to learn more about the effect of two different moisturizers on skin that is affected by eczema. The two different skin creams to be used include Aveeno Daily Moisturizing Sheer Hydration Lotion (which is available over the counter) and EpiCeram (available with prescription only). Both products are FDA approved and are being used according to labeling. This study will only require 3 visits over the course of a week. We are currently recruiting people with atopic dermatitis, ages 0-40.
If you are interested in learning more about the study or scheduling a screening visit, you can contact the study coordinator, Melanie Shojinaga, at email@example.com.
The purpose of this study is to determine the safety and efficacy of a study drug delivered via injection given weekly or every other week, in subjects with Eosinophilic Esophagitis (EoE). There are 3 parts to this study, Part A, Part B, and Part C. Subjects will participate in either Part A or Part B, and in Part C. Everyone in Part C will receive the study drug. Your participation in this study may last up to 18 months. If you agree to participate in this study, you will come in to the clinic for approximately 20 scheduled visits. We are currently recruiting 12 year olds or older with EoE.
If you are interested in learning more about the study or scheduling a screening visit, you can contact the study coordinator Melanie Shojinaga at firstname.lastname@example.org.
Regeneron Dupi 1702 Peanut Study
Condition: Peanut Allergy
Age Group: 6-17 yo
Duration: 44 weeks
Description: The purpose of this study is to investigate the safety and efficacy of an investigational product for peanut allergy. All enrolled patients will receive either the investigational product (dupilumab) or placebo as an injection. We are currently recruiting people with peanut allergy, ages 6-17. This study will take a total of 44 weeks.
Contact: If you are interested in learning more about the study or scheduling a screening visit, you can contact the study coordinator, MacKenzie Cox, at email@example.com.
Regeneron 16114 Dupilumab/AR101 Peanut Study
This study is researching dupilumab, an injection, and oral immunotherapy (OIT). These are both investigational treatments, which means neither has been approved by the FDA for food allergy. This study will test the safety and efficacy of dupilumab when added to OIT in children with a peanut allergy. The OIT used in this study is AR101, used to desensitize those with a peanut allergy by gradually increasing exposure to peanut protein. Dupilumab (the investigational drug) or placebo will be given as a shot in the clinic the first 2 times and then biweekly at home throughout the study. This study seeks peanut-allergic participants of 6-17 years of age. The study will last between 48 to 72 weeks, including: 6 to 8 weeks of screening, 4 weeks of predosing with the investigational drug (dupilumab or placebo), 24 weeks of treatment with the investigational drug (dupilumab or placebo) + AR101, 24 weeks of continued treatment (called maintenance treatment), if the patient is eligible, with the investigational drug (dupilumab or placebo) + AR101, and 12 weeks of follow-up. This study also includes closely monitored food challenges.
If you are interested, please contact us at firstname.lastname@example.org.
Please visit www.clinicaltrials.gov to learn more about the clinical trials offered at our Center.
Our studies include a wide range of patients, representing a diverse group of ages, ethnicities and socioeconomic backgrounds. Our Center offers equal opportunity to all people with allergies, so long as they are eligible based on study parameters.